Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2007

Gene Logic Tasked with Repositioning Merck Serono Drugs

  • Gene Logic plans to research alternative development paths for several Merck Serono clinical candidates under a drug-repositioning agreement. All the candidates were discontinued or de-prioritized for reasons other than safety, according to the companies.

    Gene Logic will receive success-based milestones and royalties. If Gene Logic identifies a new therapeutic use for any compound, the company has the right to exclusively license the drug so long as Merck Serono opts out of development. Merck Serono then would be entitled to success-based milestone and royalty payments on these licensed candidates.

    Gene Logic has similar repositioning collaborations with Eli Lilly, Lundbeck, Abbott, Organon, Roche, and Pfizer.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »